New chemical entity exclusivity and the four-year door for generics

Thirty-one brand drug applications in FDA's Orange Book carry a new chemical entity exclusivity date that falls in 2027. For each of them, the first day a generic company could submit an application challenging the brand's patents falls a year earlier, four years after approval. GxRadar counted those dates in the Orange Book data files FDA posted in October 2026¹⁰.

New chemical entity exclusivity, usually shortened to NCE exclusivity, is the first barrier a generic faces when a new molecule reaches the market. It comes from the Drug Price Competition and Patent Term Restoration Act of 1984¹, better known as Hatch-Waxman, and it works differently from every other exclusivity. Instead of delaying approval, it delays the filing. This piece explains the five-year rule, the four-year exception, the shorter three-year exclusivity for changes to older drugs, and the codes that mark each one in the Orange Book.

Five years, counted from approval

Section 505(j)(5)(F)(ii) of the Federal Food, Drug, and Cosmetic Act holds the rule. If FDA approves a drug "no active moiety" of which has been approved before, the statute says², no generic application referring to it "may be submitted" until five years after that approval. FDA's regulation at 21 CFR 314.108³ defines a new chemical entity as "a drug that contains no active moiety that has been approved by FDA" in any other new drug application.

An active moiety is the working part of the molecule. FDA's definitions section⁴ calls it the molecule or ion responsible for the drug's action, "excluding those appended portions" that make it an ester, a salt or another noncovalent derivative. A new salt of an old drug is therefore no new chemical entity. Congress wrote that reading into the statute in April 2021, when Public Law 117-9 replaced the older phrase "active ingredient (including any ester or salt of the active ingredient)" with "active moiety," according to the amendment notes². The same law repealed a 10-year exclusivity that had covered drugs approved between Jan. 1, 1982, and Sept. 24, 1984.

Because NCE exclusivity blocks submission, its real length is longer than five years. FDA review takes time after an application is filed, so a generic filed on the first permitted day still cannot launch on day one of year six. If patents or other exclusivities still block it when review is done, FDA can issue a tentative approval instead.

The four-year door for patent challenges

Congress made one exception. A generic applicant may file after four years if its application contains a paragraph IV certification, a statement that the brand's listed patents are invalid or will not be infringed.

Filing at year four comes with a trade. Ordinarily a patent suit against a generic triggers a 30-month stay of approval. When the suit comes in the year that begins 48 months after brand approval, section 505(j)(5)(F)(ii)² extends the stay as needed so that 7.5 years pass from the brand's approval. Pediatric exclusivity, under section 505A⁵, adds six months to each of these markers.

That last row comes from the Generating Antibiotic Incentives Now provisions Congress added in July 2012. For a drug FDA designates as a qualified infectious disease product, section 505E⁶ says the four- and five-year periods, the three-year periods and the seven-year orphan period "shall be extended by 5 years." The October data list unexpired GAIN codes on 37 brand applications.

Patent challengers at year four can also be competing for 180-day exclusivity, which goes to the first applicant or applicants to file. FDA's paragraph IV certification list¹² records the date of each drug's first such submission.

Three years for new clinical investigations

A second Hatch-Waxman exclusivity covers drugs whose active moiety has been approved before. If an application or supplement contains "reports of new clinical investigations (other than bioavailability studies) essential to the approval" and run or sponsored by the applicant, FDA may not make a generic approval effective² for those conditions of approval for three years.

Three-year exclusivity differs from NCE exclusivity in two ways. It blocks approval, so a generic can be filed and reviewed during the period. And it protects only the change the new studies supported, such as a new indication, strength, dosage form or patient population. A generic of the original product can still be approved for everything else. FDA's draft guidance from March 2026⁷ describes how "exclusivity-protected information" can be "carved out of the labeling while making available non-protected information," the practice GxRadar covers in generic labeling and carve-outs.

Everything turns on the word essential. Under FDA's rule³, an investigation is essential to approval when "there are no other data available that could support approval." The March 2026 draft, posted on FDA's guidance page⁸, says FDA does not treat a study as essential simply because the applicant conducted it and submitted it.

Reading the codes

The Orange Book marks each exclusivity with a code and an expiration date. FDA's 2026 edition⁹ lists NCE for new chemical entity; NP, NDF, NS, NPP, NR, NC and NE for new products, dosage forms, strengths, patient populations, routes, combinations and esters or salts; and numbered I, D and M codes for new indications, dosing schedules and miscellaneous changes. Most of the second group are three-year exclusivities. FDA cautions that the codes "do not necessarily identify, with specificity, the actual scope of exclusivity."

GxRadar tallied unexpired codes by family in the October 2026 data files, counting each application once per family.

FDA's plain-language summary¹¹ adds a distinction that trips up many readers. Exclusivity is granted by FDA at approval and "may run concurrently with a patent but need not do so." A drug can be off patent and still protected, or patented with its exclusivity long expired. GxRadar's piece on patent thickets covers the patent side.

The NCE calendar ahead

Because the NCE date is set by approval, the Orange Book doubles as a schedule. In the October 2026 files, unexpired NCE codes run out as follows.

An NCE date is a filing date. When generics actually reach the market depends on patents, litigation and FDA review, which is why first generics for many of these drugs will arrive years later. FDA's yearly first generic approvals and GxRadar's approvals tracker show when that happens. The 39 applications with NCE dates in 2028 reach their four-year mark during 2027.